en · de · es · fr · pt
semax-notes.peptides6823.com › Topic › Background And Development — What the Evidence Shows

Background And Development — What the Evidence Shows

By Editorial Desk · published 2025-08-19 · last reviewed 2025-09-29 · Topic

A practical reference on ACTH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-09-29. Anything still debated is marked as such rather than presented as settled.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax Peptide Background and Identity

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideAnalog of an ACTH fragment
Amino acid lengthSeven residuesMet-Glu-His-Phe-Pro-Gly-Pro
OriginMoscow, 1980sInstitute of Molecular Genetics
Approved regionsRussia and some neighboring statesNot cleared in Western markets
Common trade namesMultiple national brandsSold as a nasal formulation

Semax Background and Chemistry

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.

Related pages on this site

Semax 的分子背景与结构

该化合物于二十世纪八十年代在俄罗斯被开发,相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性,而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示,这一方向促成了多个相关短肽的合成与筛选,而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。

研究兴趣主要集中在神经营养因子相关的路径上,包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升,但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验,人体对照研究数量有限。因此,该化合物的作用机制在文献中属于活跃讨论,而非已经确立的定论。

Notes from published material

=== The Healing Foundation === In 1998, as Treasurer of the British Association of Plastic, Reconstructive, and Aesthetic Surgeons (BAPRAS), Brough and his fellow Trustees established The Healing Foundation. Building on the groundwork laid by the Phoenix Appeal, The Healing Foundation aimed to advance research into surgical and psychological healing techniques for individuals with disfiguring conditions. Various UK medical membership bodies provided support to The Healing Foundation as Partner Member Organisations. These partnerships bolstered the charity's credibility, networking capabilities, and financial resources.These organisations were BAPRAS, the British Association of Aesthetic Surgeons, the British Psychological Society, the Craniofacial Society of Great Britain and Ireland, the British Burns Association, and the British Society for Surgery of the Hand.

People living through the post–Cold War period witnessed rapid economic transformation and political integration in much of Central and Eastern Europe, particularly in states that later joined the European Union and NATO. At the same time, parts of the former Soviet Union experienced severe economic dislocation, declining living standards, and sharp reductions in life expectancy during the transition to market economies. Countries such as the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, and Slovakia experienced economic reconstruction, growth and fast integration with EU and NATO, while some of their eastern neighbors created hybrids of free market oligarchy system, post-communist corrupted administration and dictatorship. Russia and some other Soviet successor states faced a chaotic and harsh transition from a command economy to free market capitalism following the dissolution of the Soviet Union. A large percentage of the population lived in poverty, growth of the gross domestic product declined, and life expectancy dropped sharply. Living conditions also declined in some other parts of the former Eastern bloc.

The body produces approximately 2.3 pounds (1.0 kg) of carbon dioxide per day per person, containing 0.63 pounds (290 g) of carbon. In humans, this carbon dioxide is carried through the venous system and is breathed out through the lungs, resulting in lower concentrations in the arteries. The carbon dioxide content of the blood is often given as the partial pressure, which is the pressure which carbon dioxide would have had if it alone occupied the volume. In humans, the blood carbon dioxide contents are shown in the adjacent table.

Sources: en.wikipedia.org

Background from the literature

fasting blood sugar (FBS), fasting plasma glucose (FPG): 10–16 hours after eating glucose tolerance test: continuous testing postprandial glucose test (PC): 2 hours after eating random glucose test Some laboratory tests don't measure glucose levels directly from body fluids or tissues but still indicate elevated blood sugar levels. Such tests measure the levels of glycated hemoglobin, other glycated proteins, 1,5-anhydroglucitol etc. from blood.

Lawrencium is a synthetic chemical element; it has symbol Lr (formerly Lw) and atomic number 103. It is named after Ernest Lawrence, inventor of the cyclotron, a device used to discover many artificial radioactive elements. A radioactive metal, lawrencium is the eleventh transuranium element, the third transfermium, and the last member of the actinide series. Like all elements with atomic numbers over 100, lawrencium can only be produced in particle accelerators by bombarding lighter elements with charged particles. Fourteen isotopes of lawrencium are known; the most stable is 266Lr with half-life 11 hours, but the shorter-lived 260Lr (half-life 2.7 minutes) is most commonly used in chemistry because it can be produced on a larger scale. Chemistry experiments confirm that lawrencium behaves as a heavier homolog to lutetium in the periodic table, and is trivalent. It could thus also be classified as the first of the 7th-period transition metals. Its electron configuration is anomalous for its position in the periodic table, having an s2p configuration instead of the s2d configuration of its homolog lutetium. However, this does not appear to affect lawrencium's chemistry. In the 1950s, 1960s, and 1970s, many claims of synthesis of element 103 of varying quality were made by laboratories in the Soviet Union and the United States. The priority of the discovery and therefore the name of the element was disputed between Soviet and American scientists.

When urine pH is abnormal, the urinary recovery of amphetamine may range from a low of 1% to a high of 75%, depending mostly upon whether urine is too basic or acidic, respectively. Following oral administration, amphetamine appears in urine within 3 hours. Roughly 90% of ingested amphetamine is eliminated 3 days after the last oral dose. Lisdexamfetamine is a prodrug of dextroamphetamine. It is not as sensitive to pH as amphetamine when being absorbed in the gastrointestinal tract. Following absorption into the blood stream, lisdexamfetamine is completely converted by red blood cells to dextroamphetamine and the amino acid L-lysine by hydrolysis via undetermined aminopeptidase enzymes. This is the rate-limiting step in the bioactivation of lisdexamfetamine. The elimination half-life of lisdexamfetamine is generally less than 1 hour. Due to the necessary conversion of lisdexamfetamine into dextroamphetamine, levels of dextroamphetamine with lisdexamfetamine peak about one hour later than with an equivalent dose of immediate-release dextroamphetamine. Presumably due to its rate-limited activation by red blood cells, intravenous administration of lisdexamfetamine shows greatly delayed time to peak and reduced peak levels compared to intravenous administration of an equivalent dose of dextroamphetamine. The pharmacokinetics of lisdexamfetamine are similar regardless of whether it is administered orally, intranasally, or intravenously. Hence, in contrast to dextroamphetamine, parenteral use does not enhance the subjective effects of lisdexamfetamine.

Sources: en.wikipedia.org

Reference notes

== External links == "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Hommes et femmes" [Men and women]. Observatoire des Inégalités (in French). Archived from the original on February 19, 2007. "Lutte contre les discriminations et promotion de l'égalité" [Fighting discrimination and promoting equality]. Defenseurs des droits (in French). Archived from the original on June 13, 2017. "La discrimination des femmes : un sujet d'actualité" [Discrimination against women: a topical issue]. CentrOjeunes (in French). December 6, 2012. Archived from the original on August 8, 2016. "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Haut conseil à l'égalité des droits" [High Council for Equal Rights]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on May 22, 2013. "Secrétariat d'état chargé de l'égalité entre femmes et hommes et de la lutte contre les discriminations" [State Secretariat for Gender Equality and Anti-Discrimination]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on January 7, 2013. "Maison de la justice et du droit" [House of Justice and Law] (in French). Archived from the original on April 12, 2013. "Association européenne contre les Violences faites aux Femmes au Travail" [European Association Against Violence Against Women at Work] (in French).

Intestinal desmosis is a medical condition implicated in gut motility disorder and chronic constipation. Desmosis can be observed as the absence of the tendinous plexus layer and connective tissue fibers.

Mutations that prevent the formation of MinE rings result in the MinCD zone extending well beyond the polar zones, preventing FtsZ to polymerize and to perform cell division. MinD requires a nucleotide exchange step to re-bind to ATP so that it can re-associate with the membrane after MinE release. The time lapse results in a periodicity of Min association that may yield clues to a temporal signal linked to a spatial signal. In vivo observations show that the oscillation of Min proteins between cell poles occurs approximately every 50 seconds. Oscillation of Min proteins, however, is not necessary for all bacterial cell division systems. Bacillus subtilis has been shown to have static concentrations of MinC and MinD at the cell poles. This system still links cell size to the ability to form a septum via FtsZ and divide.

=== Labour === Tea production in Kenya, Malawi, Rwanda, Tanzania, and Uganda uses child labour, according to the U.S. Department of Labor's List of Goods Produced by Child Labor or Forced Labor. Workers who pick and pack tea on plantations in developing countries can face harsh working conditions and may earn below the living wage. In countries such as Bangladesh, trade unions such as the Bangladesh Tea Workers Women's Forum, led by Gita Rani Kanu, have emerged to campaign for better working conditions for tea workers.

Sources: en.wikipedia.org

Frequently asked questions

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Is Semax an approved medication anywhere?

It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.

What is the relationship to ACTH?

Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.

What is Semax made of?

It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.

Network